Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department for Education:
To ask the Secretary of State for Education, when amendments to the Children Act 1989 to strengthen protections for children in local authority care will be brought forward, in the context of the recommendations of the Independent Inquiry into Child Sexual Abuse.
Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)
Our ‘Tackling child sexual abuse: progress update’, published in April 2025, set out the government’s work to respond to the Independent Inquiry into Child Sexual Abuse’s recommendation to amend the Children Act 1989. The update is available at: https://www.gov.uk/government/publications/tackling-child-sexual-abuse-progress-update.
The department will publish new national standards and statutory guidance for advocacy for children and young people and has committed to establishing a Child Protection Authority. In December 2025, we published the consultation on the authority’s scope, functions and powers, with the aim of making the system clearer, more unified and ensure there is ongoing improvement through effective evidence-based support for practitioners.
Further, the Children’s Wellbeing and Schools Bill marks the biggest overhaul of children’s social care in a generation with a sharp focus on protecting children. This includes measures to establish multi-agency child protection teams in every local authority area, improve information sharing between agencies, and automatically include education and childcare settings in multi-agency safeguarding arrangements.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department for Education:
To ask the Secretary of State for Education, what assessment her Department has made of the potential merits of implementing the recommendation of the Independent Inquiry into Child Sexual Abuse to appoint a Cabinet level Minister with responsibility for children.
Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)
In April 2025, the government published its Tackling Child Sexual Abuse Progress Update, which responded to each of the 20 recommendations form the final report of the Independent Inquiry into Child Sexual Abuse.
The government agrees with the importance of having a clear focus on children across government, including at Cabinet level. My right hon. Friend, the Secretary of State for Education, is the Cabinet minister for children and a Keeping Children Safe ministerial board has been established to drive and mainstream the strong collective cross-government focus on children’s wellbeing, safety and opportunity. This will bring together ministers from the government departments with a key role on issues affecting children.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps are being taken to guarantee access to specialist therapeutic support services for child victims of sexual abuse, in the context of the recommendation of the Independent Inquiry into Child Sexual Abuse.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Last April, we committed to ambitious proposals in response to recommendation 16 from the Independent Inquiry into Child Sexual Abuse. As part of our response to delivering on that promise, we are investing up to £50 million to roll out the internationally recognised Child House model across all National Health Service regions in England.
The model brings health, justice, and social care professionals together under one roof to reduce trauma and deliver the care children deserve in a safe, child-centred environment. Too often, children are asked to retell their experiences to multiple professionals, reliving their trauma with each repetition. The Child House model changes this.
This investment sits alongside our wider work to transform children’s mental health services. We are committed to reducing waiting times for specialist Child and Adolescent Mental Health Service support, as set out in our Medium-Term Planning Framework. We are accelerating the rollout of mental health support teams in schools and colleges, working towards full national coverage by 2029. And we are investing an additional £13 million to pilot enhanced training so school-based mental health teams can better support young people with complex needs, including trauma.
Together, these actions represent a fundamental shift by treating child sexual abuse as the healthcare priority it is and ensuring that victims and survivors receive the very best support to rebuild their lives.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits of providing limited amounts of non-mRNA COVID-19 vaccines available for patients with clinical contraindications to mRNA vaccines, including through the importation of products already authorised by trusted international regulators.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of establishing a national referral pathway or specialist hub for people who cannot receive mRNA vaccines to ensure equitable access to appropriate COVID-19 vaccinations.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people are clinically unable to receive mRNA-based COVID-19 vaccines; and how this figure has been derived.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to prevent serum Clozapine blood samples from being lost in transit within the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No specific assessment has been made of the reliability of current systems for transporting and processing serum Clozapine blood samples across National Health Service providers. Operational responsibility for the collection, transport, and processing of clozapine blood samples lies with individual NHS providers and their commissioned pathology and courier services. Further information on sample type and transport stability is available via individual NHS trust laboratory webpages.
Testing for clozapine levels is carried out within the same accredited pathology framework used for other biochemical assays, with defined requirements for sample collection, labelling, storage and transport to maintain sample integrity. Laboratories providing clozapine assays hold UKAS ISO 15189 accreditation and are required to undertake internal quality control and participate in national External Quality Assessment schemes to ensure accuracy and reproducibility of results.
Samples are transported through contracted courier services operating temperature controlled logistics, chain of custody processes and turnaround time requirements. These arrangements form part of routine clinical governance, incident reporting and performance management across NHS pathology services to prevent sample loss and provide assurance on the reliability of testing. Detailed operational arrangements are managed locally by individual pathology providers.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the reliability of current systems for transporting and processing serum Clozapine blood samples across NHS providers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No specific assessment has been made of the reliability of current systems for transporting and processing serum Clozapine blood samples across National Health Service providers. Operational responsibility for the collection, transport, and processing of clozapine blood samples lies with individual NHS providers and their commissioned pathology and courier services. Further information on sample type and transport stability is available via individual NHS trust laboratory webpages.
Testing for clozapine levels is carried out within the same accredited pathology framework used for other biochemical assays, with defined requirements for sample collection, labelling, storage and transport to maintain sample integrity. Laboratories providing clozapine assays hold UKAS ISO 15189 accreditation and are required to undertake internal quality control and participate in national External Quality Assessment schemes to ensure accuracy and reproducibility of results.
Samples are transported through contracted courier services operating temperature controlled logistics, chain of custody processes and turnaround time requirements. These arrangements form part of routine clinical governance, incident reporting and performance management across NHS pathology services to prevent sample loss and provide assurance on the reliability of testing. Detailed operational arrangements are managed locally by individual pathology providers.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department for Education:
To ask the Secretary of State for Education, whether she plans to introduce a mandatory registration of staff working in children's homes.
Answered by Josh MacAlister - Parliamentary Under-Secretary (Department for Education)
The government set out its position regarding professional registration of the children’s homes workforce in its ’Tackling child sexual abuse: progress update’, published on GOV.UK in April 2025 here: https://www.gov.uk/government/publications/tackling-child-sexual-abuse-progress-update.
The immediate focus is to develop workforce standards and review sector qualifications to ensure staff working in children’s homes are equipped with the knowledge and skills they need to provide the best possible care, and have access to high quality continuing professional development.
This will provide the essential foundation for looking at the risks and benefits of a registration model for care staff, including a wider consultation in the longer term.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Ministry of Housing, Communities and Local Government:
To ask the Secretary of State for Housing, Communities and Local Government, pursuant to the answer of 15 January 2026 to Question 103696, how any proposed non statutory definition of anti Muslim hatred or Islamophobia may be used by public authorities outside the criminal justice system.
Answered by Miatta Fahnbulleh - Parliamentary Under-Secretary (Housing, Communities and Local Government)
Ministers are taking the time to review and consider the independent Working Group’s advice before confirming next steps in due course.
As per the Working Group's Terms of Reference, a definition could provide the government and other relevant bodies with a greater understanding of unacceptable treatment and prejudice against Muslim communities.